FDA Grants Breakthrough Designation for Quest’s Adeno-Associated Virus Test
Quest Diagnostics announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. FDA.
Read MorePosted by Andy Lundin | Aug 30, 2023 | Diagnostic Technologies |
Quest Diagnostics announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. FDA.
Read MorePosted by Chris Wolski | Aug 22, 2023 | Miscellaneous |
In the wake of COVID-19 there is a clear benefit for a collaborative approach between clinical labs and the entire health care enterprise.
Read MorePosted by Andy Lundin | Aug 17, 2023 | Sequencing Systems |
The study sequenced the genomes of infants with seizures to understand the strengths of early, broad genome sequencing of infantile epilepsy.
Read MorePosted by Andy Lundin | Aug 16, 2023 | Transfusion & Transplantation Tests |
The Prospera Lung transplant assessment test has met coverage requirements from the CMS and Molecular Diagnostics Services Program.
Read MorePosted by Andy Lundin | Aug 15, 2023 | Cancer |
The population genomics program will identify participants’ risk for cancer and other life-threatening diseases with a single test.
Read More